相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors
Matthew J. Mosquera et al.
ADVANCED MATERIALS (2022)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
David F. Penson et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2022)
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review
Davide Loizzo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Fanying Tang et al.
SCIENCE (2022)
Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
Gregory L. Branigan et al.
CANCER MEDICINE (2022)
Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer
Burcu F. Darst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy
Danielle P. Johnson et al.
CANCERS (2021)
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb et al.
EUROPEAN UROLOGY (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
Felice Crocetto et al.
DIAGNOSTICS (2021)
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Dae-Hwan Kim et al.
CLINICAL CANCER RESEARCH (2021)
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity
Ivana Grbesa et al.
CELL REPORTS (2021)
Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
Alessandro Sciarra et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Tommy Nyberg et al.
EUROPEAN UROLOGY (2020)
Targeting DNA repair in cancer: current state and novel approaches
Apostolos Klinakis et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies
Amir Iravani et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion
Jianlin Wang et al.
AGING-US (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips et al.
JAMA ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways
Huairui Yuan et al.
CANCER CELL (2020)
The DNA methylation landscape of advanced prostate cancer
Shuang G. Zhao et al.
NATURE GENETICS (2020)
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2020)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer
Yunfeng Bai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Isaac E. Kim et al.
BMC UROLOGY (2019)
KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN
Zhe Hong et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc
Ching-Yu Lin et al.
CANCERS (2019)
Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer
Qipeng Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Yuan Fang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J. Khalaf et al.
LANCET ONCOLOGY (2019)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies et al.
NATURE REVIEWS UROLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer
Aishwarya Pawar et al.
CELL REPORTS (2018)
Alternative splicing in prostate cancer
Alec Paschalis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo
Gang Shen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Prostate Luminal Progenitor Cells in Development and Cancer
Dingxiao Zhang et al.
TRENDS IN CANCER (2018)
Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
Bram L. T. Ramaekers et al.
PHARMACOECONOMICS (2017)
Rationale for the development of alternative forms of androgen deprivation therapy
Sangeeta Kumari et al.
ENDOCRINE-RELATED CANCER (2017)
Autophagic cell death with hydroxychloroquine in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
Mridula Annette George et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
Xiangpeng Dai et al.
NATURE MEDICINE (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal et al.
NATURE COMMUNICATIONS (2017)
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells
Stephen Wilson et al.
ONCOTARGET (2017)
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Isabel Coutinho et al.
ENDOCRINE-RELATED CANCER (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
Qiang Dang et al.
MOLECULAR ONCOLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators
Emeli M. Nilsson et al.
ONCOTARGET (2015)
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
R. Ferraldeschi et al.
ONCOGENE (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities
Dante Rotili et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
KDM4B as a Target for Prostate Cancer: Structural Analysis and Selective Inhibition by a Novel Inhibitor
Chia-Han Chu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program
Hong-Jian Jin et al.
NATURE COMMUNICATIONS (2014)
Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity
Changmeng Cai et al.
CELL REPORTS (2014)
Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer
Zhu A. Wang et al.
CELL REPORTS (2014)
The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man
Naomi L. Sharma et al.
CANCER CELL (2013)
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
Dana Rathkopf et al.
CANCER JOURNAL (2013)
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer
Vasundhra Kashyap et al.
MOLECULAR ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Resistance Emerges to Second-Generation Antiandrogens in Prostate Cancer
William G. Nelson et al.
CANCER DISCOVERY (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Histological variants of prostatic carcinoma and their significance
Peter A. Humphrey
HISTOPATHOLOGY (2012)
Regulation of Androgen Receptor-dependent Transcription by Coactivator MED1 Is Mediated through a Newly Discovered Noncanonical Binding Motif
Feng Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Drug resistance in metastatic castration-resistant prostate cancer
Bostjan Seruga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Molecular genetics of prostate cancer: new prospects for old challenges
Michael M. Shen et al.
GENES & DEVELOPMENT (2010)
Molecular cell biology of androgen receptor signalling
Nigel C. Bennett et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor
X. Edward Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival
Hideyuki Akaza et al.
CANCER (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer
Emma L. Clark et al.
CANCER RESEARCH (2008)
Ductal prostate cancer: Contemporary management and outcomes
Eduardo Orihuela et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression
Melanie Wissmann et al.
NATURE CELL BIOLOGY (2007)
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence
Philip Kahl et al.
CANCER RESEARCH (2006)
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
David Gillatt
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
E Metzger et al.
NATURE (2005)
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: Interim results of a randomized study in Japanese patients
H Akaza et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
The program of androgen-responsive genes in neoplastic prostate epithelium
PS Nelson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The FXXLF motif mediates androgen receptor-specific interactions with coregulators
B He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression
NR Mucci et al.
HUMAN PATHOLOGY (2000)
分享论文
